Gilberto de Castro Junior
Gilberto de Castro Junior
Médico Assistente Doutor, Serviço de Oncologia Clínica, Instituto do Câncer do Estado de São Paulo
Dirección de correo verificada de lim24.fm.usp.br
Título
Citado por
Citado por
Año
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ...
The Lancet 387 (10027), 1540-1550, 2016
35842016
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E De Azambuja, F Cardoso, G de Castro, M Colozza, MS Mano, ...
British journal of cancer 96 (10), 1504-1513, 2007
9422007
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
5532017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
D Cameron, MJ Piccart-Gebhart, RD Gelber, M Procter, A Goldhirsch, ...
The Lancet 389 (10075), 1195-1205, 2017
3952017
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum …
JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ...
The Lancet Oncology 16 (5), 583-594, 2015
314*2015
Side effects of approved molecular targeted therapies in solid cancers
C Widakowich, G de Castro Jr, E De Azambuja, P Dinh, A Awada
The oncologist 12 (12), 1443-1455, 2007
3082007
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ...
The Lancet 393 (10167), 156-167, 2019
3012019
Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation
P Lothaire, E de Azambuja, D Dequanter, Y Lalami, C Sotiriou, G Andry, ...
Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2006
1982006
Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
K Cocks, MT King, G Velikova, G de Castro Jr, MM St-James, PM Fayers, ...
European journal of cancer 48 (11), 1713-1721, 2012
1852012
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥ 1%: open-label …
G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, ...
Journal of Clinical Oncology 36 (18_suppl), LBA4-LBA4, 2018
1802018
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro Jr, ...
The Lancet 394 (10212), 1915-1928, 2019
1682019
Regenerative potential of leucocyte‐and platelet‐rich fibrin. Part A: intra‐bony defects, furcation defects and periodontal plastic surgery. A systematic review and meta‐analysis
AB Castro, N Meschi, A Temmerman, N Pinto, P Lambrechts, W Teughels, ...
Journal of clinical periodontology 44 (1), 67-82, 2017
1212017
Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm)
G de Castro Junior, F Puglisi, E de Azambuja, NS El Saghir, A Awada
Critical reviews in oncology/hematology 59 (1), 40-50, 2006
1092006
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised …
L Paz-Ares, J Mezger, TE Ciuleanu, JR Fischer, J von Pawel, M Provencio, ...
The Lancet Oncology 16 (3), 328-337, 2015
1082015
Regenerative potential of leucocyte‐and platelet‐rich fibrin. Part B: sinus floor elevation, alveolar ridge preservation and implant therapy. A systematic review
AB Castro, N Meschi, A Temmerman, N Pinto, P Lambrechts, W Teughels, ...
Journal of clinical periodontology 44 (2), 225-234, 2017
1012017
LBA8_PR KEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G De Castro Jr, ...
Annals of Oncology 29 (suppl_8), mdy424. 045, 2018
952018
Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study
AG de Lima, RC Villar, G de Castro Jr, R Antequera, E Gil, ...
International Journal of Radiation Oncology* Biology* Physics 82 (1), 270-275, 2012
872012
The use of leucocyte and platelet‐rich fibrin in socket management and ridge preservation: a split‐mouth, randomized, controlled clinical trial
A Temmerman, J Vandessel, A Castro, R Jacobs, W Teughels, N Pinto, ...
Journal of clinical periodontology 43 (11), 990-999, 2016
862016
Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
B Haaland, P San Tan, G de Castro Jr, G Lopes
Journal of Thoracic Oncology 9 (6), 805-811, 2014
862014
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell …
D Rischin, KJ Harrington, R Greil, D Soulieres, M Tahara, G de Castro, ...
Journal of Clinical Oncology 37 (15_suppl), 6000-6000, 2019
752019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20